

Influenza

Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza

Trial Status
Completed

Trial Runs In
28 Countries

Trial Identifier
NCT03684044 2018-001416-30
CP40617

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the efficacy, safety, and pharmacokinetics of baloxavir marboxil in combination with a standard-of-care (SOC) neuraminidase inhibitor (NAI) (i.e., oseltamivir, zanamivir, or peramivir) compared with a matching placebo in combination with a SOC NAI in hospitalized patients with influenza.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT03684044 2018-001416-30 CP40617
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 12 Years

Healthy Volunteers
No